T-cell immunoreceptor with Ig and ITIM domains, better known as TIGIT, has emerged as one of the most closely watched immune checkpoint targets since the rise of PD-1/PD-L1 blockade. TIGIT is expressed on activated T cells, natural killer cells, and regulatory T cells, and it binds to the ligands CD155 and CD112 found on tumor cells and antigen-presenting cells. By blocking this interaction, TIGIT inhibitors free up CD226-mediated signaling on NK and CD8+ T cells, reactivating the immune system’s ability to recognize and destroy cancer cells. While no TIGIT-targeted therapy has secured regulatory approval yet, the pipeline is active, with several late-stage candidates advancing across multiple solid tumor types including non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma, endometrial cancer, head and neck squamous cell carcinoma, and hepatocellular carcinoma.
Understanding the TIGIT Inhibitors Market Landscape
The competitive space is shaped by major pharmaceutical and biotech players, including Roche, Merck, AstraZeneca, iTeos Therapeutics, and Arcus Biosciences, all pursuing distinct molecules and combination strategies. Because TIGIT is frequently co-expressed with PD-1 on exhausted immune cells, most development programs favor combination approaches rather than monotherapy, pairing TIGIT blockade with existing PD-1/PD-L1 inhibitors to achieve synergistic antitumor activity. This dual-checkpoint rationale has driven expanding clinical evaluation across NSCLC, gastric and gastroesophageal junction cancer, biliary tract cancer, and other advanced solid tumors, broadening the eventual commercial opportunity for the drug class. The field is also evolving toward next-generation formats, such as bispecific antibodies that simultaneously engage TIGIT and PD-1, aiming to simplify treatment regimens while improving efficacy.
TIGIT Inhibitors Market Size and Growth Outlook
Interest in the segment’s expansion is closely tied to disease burden. In 2024, the United States alone recorded roughly 204,820 incident cases of NSCLC, while the 7MM (US, EU4, UK, and Japan) saw approximately 150,900 head and neck squamous cell carcinoma cases. Japan reported nearly 121,910 NSCLC cases the same year. Renal cell carcinoma accounted for 80% of kidney cancer cases in the UK, and lung cancer remains the most diagnosed cancer across Europe. Rising diagnosis rates, combined with growing physician awareness of checkpoint combination strategies, are expected to fuel demand once an approved therapy reaches the market. Forecast models covering 2022 through 2036 anticipate meaningful growth as ongoing Phase III programs mature and, if successful, transition toward regulatory filing and commercial launch between 2026 and 2036.
Leading TIGIT Inhibitors Companies and Their Pipelines
Arcus Biosciences’ domvanalimab, a humanized IgG1 monoclonal antibody, is being tested in NSCLC and upper gastrointestinal malignancies through trials such as STAR-221, STAR-121, and PACIFIC-8, with October 2025 data from the EDGE-Gastric study reinforcing its combination potential. AstraZeneca’s rilvegostomig, developed alongside Compugen and supported by a licensing arrangement updated in December 2025, is a bispecific molecule targeting both PD-1 and TIGIT, under evaluation in Gastric01 and ARTEMIDE-HCC01, and explored alongside Daiichi Sankyo’s antibody-drug conjugate DATROWAY. Roche’s tiragolumab continues in hepatocellular carcinoma and NSCLC settings, though its SKYSCRAPER-01 study failed its overall survival endpoint, and September 2025 ESMO data for tiragolumab in HCC likewise missed the co-primary progression-free survival goal. iTeos Therapeutics discontinued belrestotug, incurring a substantial impairment charge, while programs like etigilimab and AGEN1777 were also shelved by their respective sponsors, underscoring the class’s mixed clinical track record.
Evolving TIGIT Inhibitors Treatment Market Dynamics
Despite these setbacks, industry sentiment has not collapsed. Ongoing Phase III programs for domvanalimab and rilvegostomig remain closely watched value drivers, and any positive readout could meaningfully reshape competitive positioning in immuno-oncology. Reimbursement and access considerations will also play a defining role once a therapy is approved, given variability in health technology assessments across the US, EU4, UK, and Japan. Future research directions include identifying predictive biomarkers for patient selection and exploring alternative modalities such as antibody-drug conjugates and CAR-T approaches directed at TIGIT. As trial data continues to mature through the remainder of this decade, the balance between clinical setbacks and combination-therapy promise will determine how quickly this checkpoint class transitions from investigational to commercially available treatment.
Latest Reports Offered by Delveinsight
injectable drug delivery devices | hypoplastic left heart syndrome hlhs market | tay-sachs market | ventricular fibrillation market | artificial iris market | erectile dysfunction market | apheresis market | listeriosis market | mallory-weiss tear market | scleritis market | paget’s disease market | sepsis market | iron deficiency anemia market | oral electrolyte solutions market | erythromelalgia market | exophthalmos market | chronic hemodialysis market | diabetic retinopathy market | keratisis market | dilators market | car-t market | transdermal drug delivery devices | intracranial pressure monitoring devices market | bladder scanners market | vascular imaging devices market | interventional cardiology devices market | atypical teratoid rhabdoid tumors market | hepatitis c market | lice infestations market
About Delveinsight
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Kanishk